Articles From: Coca-Cola Enterprises, Inc. Reports Fourth-Quarter and Full-Year 2014 Results to Navigant Reports Fourth Quarter and Full Year 2014 Financial Results


2015/2/12
Coca-Cola Enterprises, Inc. (NYSE: CCE)(Euronext Paris: CCE) today reported full-year 2014 earnings per diluted share of $2.63, or $2.85 on a comparable basis.
Sign-up for Coca-Cola Enterprises, Inc. Reports Fourth-Quarter and Full-Year 2014 Results investment picks
2015/2/12
-- Fourth quarter contract revenue of $80.7 million, up 35% from 2013 --
Sign-up for AMRI Announces Fourth Quarter and Full Year 2014 Results investment picks
2015/2/12
McGraw Hill Financial Inc. (MHFI) said Thursday it had a net loss of $846 million, or $3.11 a share, after earnings of $171 million, or 62 cents a share, in the year-earlier period, weighed down by the costs of a settlement with the U.S. government.
Sign-up for McGraw Hill profit hit by legal charges investment picks
2015/2/12
PRINCETON, N.J., Feb.
Sign-up for Agile Therapeutics to Present at the 2015 RBC Capital Markets' Global Healthcare Conference investment picks
2015/2/12
Avon Products Inc. (AVP) reported on Thursday a fourth-quarter net loss that widened to $330.7 million, or 75 cents a share, from $69.1 million, or 16 cents a share, in the year-earlier period.
Sign-up for Avon Products reports wider loss, sales decline investment picks
2015/2/12
2014 fourth quarter highlights - Record revenues of $197 million, up 62% from the fourth quarter 2013, or 14.6% 'organically' - Non-GAAP EPS of $0.51 (diluted); GAAP EPS of $0.31 (diluted) - Cash generated from operations of $23.4 million 2014 full year highlights - Record revenues of $583 million, up 32% from 2013 - Non-GAAP EPS of $1.48 (diluted); GAAP EPS of $0.83 (diluted) - Cash generated from operations of $51.4 million 2015 first quarter guidance - Revenues range: $180 million to $185 million - Gross margin: between 43% and 44%. YAVNE, Israel , Feb.
Sign-up for Orbotech Announces Fourth Quarter And Full Year 2014 Results investment picks
2015/2/12
Q4 revenues of $20.6 million; Non-GAAP operating income of $0.7m; Expects revenue of $21.5-23m in Q1 MIGDAL HAEMEK, Israel , Feb.
Sign-up for Camtek Announces Fourth Quarter & Full Year 2014 Results investment picks
2015/2/12
The Company Delivered Strong Revenue from Continuing Operations in Both 4th Quarter and Full-Year 2014 4th Quarter and Full-Year Revenue Each Increased 7% As a Result of Recent Legal and Regulatory Settlements, Diluted EPS from Continuing Operations Decreased to $(3.71) in the 4th Quarter and Decreased to $(1.08) for the Full Year Adjusted Diluted EPS from Continuing Operations Increased 23% to $0.95 in 4th Quarter and 20% to $3.88 for the Full Year Introduces 2015 Adjusted Diluted EPS Guidance of $4.35 to $4.45 The Company Declares New Annualized Dividend of $1.32 Per Share NEW YORK , Feb.
Sign-up for McGraw Hill Financial Reports 4th Quarter And Full-Year 2014 Results investment picks
2015/2/12
ATLANTA, Feb.
Sign-up for Numerex Receives 2015 M2M Evolution Battle of the Platforms Award investment picks
2015/2/12
Monotype Imaging Holdings Inc. (Nasdaq: TYPE), a leading provider of typefaces, technology and expertise for creative applications and consumer devices, today announced financial results for the fourth quarter and full year ended Dec.
Sign-up for Monotype Announces Fourth Quarter and Full Year 2014 Results investment picks
2015/2/12
Record Fourth Quarter Net Sales of $2.44 Billion Record Fourth Quarter Organic Net Sales Growth of 11.4% Record Fourth Quarter Segment Earnings of $411 Million and Margin of 16.8% Fourth Quarter Adjusted Diluted Earnings per Share Increases 32% to $1.15 MIAMI , Feb.
Sign-up for Jarden Reports Fourth Quarter and 2014 Full Year Results investment picks
2015/2/12
YOKNEAM ILIT, Israel and MARLBOROUGH, Mass., Feb.
Sign-up for ReWalk Robotics Reports Fourth Quarter and Year-End 2014 Financial Results investment picks
2015/2/12
Scripps Networks Interactive, Inc. (NYSE: SNI) today reported full-year and fourth-quarter 2014 operating results.
Sign-up for Scripps Networks Interactive reports full year and fourth quarter 2014 financial results investment picks
2015/2/12
Fourth-Quarter Revenue Down 12%; Up 5% in Constant Dollars1 Fourth-Quarter Operating Margin 7.3%, Up from (0.6)% in 2013 Fourth-Quarter Adjusted1 Operating Margin 9.3%, Up from 8.2% in 2013 Full-Year Revenue Down 11%; Relatively Unchanged in Constant Dollars Full-Year Operating Margin 4.5%, Up from 4.3% in 2013 Full-Year Adjusted Operating Margin 8.3%, Up from 7.9% in 2013 NEW YORK , Feb.
Sign-up for Avon Reports Fourth-Quarter and Full-Year 2014 Results investment picks
2015/2/12
Manchester United (NYSE: MANU; the “Company” and the “Group”) – one of the most popular and successful sports teams in the world - today announced financial results for the 2015 fiscal second quarter and six months ended 31 December 2014.
Sign-up for Manchester United plc 2015 Second Quarter Results investment picks
2015/2/12
Mainstreet reports 17th consecutive quarter of double digit growth Canada NewsWire CALGARY , Feb.
Sign-up for Mainstreet reports 17th consecutive quarter of double digit growth investment picks
2015/2/12
CSG International (NASDAQ: CSGS) , a global provider of interactive transaction-driven solutions and services, today announced that one of Chile’s leading telecom service providers has awarded CSG a multi-year managed services contract for the operation and management of its wholesale and roaming systems.
Sign-up for Chilean Market Leader Engages CSG International Managed Services investment picks
2015/2/12
Absolute Software Reports Fiscal 2015 Second Quarter Results Canada NewsWire Strong corporate and education sales drive a 15% increase in total Commercial Sales Contracts and a 44% growth in cash from operating activities VANCOUVER , Feb.
Sign-up for Absolute Software Reports Fiscal 2015 Second Quarter Results investment picks
2015/2/12
CICERO, Ill., Feb.
Sign-up for Broadwind to Announce Final 2014 Results on February 26 investment picks
2015/2/12
Spectrum Pharmaceuticals (NasdaqGS: SPPI) , a biotechnology company with fully integrated commercial and drug development operations with a primary focus in Hematology and Oncology, today announced results of a clinical study of Propylene Glycol (PG)-Free, Captisol-enabled Melphalan (CE Melphalan) Conditioning for Autologous Hematopoietic Stem Cell Transplantation (AHCT) in Patients with Multiple Myeloma (MM). Spectrum filed a New Drug Application (NDA) for approval of CE-Melphalan in December 2014 and expects a decision from the Food and Drug Administration (FDA) by late 2015.
Sign-up for Spectrum Pharmaceuticals Highlights Clinical Data for Captisol-Enabled™ (Propylene Glycol-Free) Melphalan at the 2015 BMT Tandem Meeting investment picks
2015/2/12
International Flavors & Fragrances Inc. (NYSE:IFF), a leading global creator of flavors and fragrances for consumer products, today reported financial results for the fourth quarter and full year ended January 2, 2015.
Sign-up for IFF Reports Strong Fourth Quarter and Full Year 2014 Results investment picks
2015/2/12
MediWound Ltd.
Sign-up for MediWound Reports Fourth Quarter and Year End 2014 Financial Results investment picks
2015/2/12
PORTLAND, Ore.
Sign-up for Rentrak Signs TV Ratings Agreement with Tennis Channel investment picks
2015/2/12
Verastem, Inc. (NASDAQ:VSTM), focused on discovering and developing drugs to treat cancer by the targeted killing of cancer stem cells, today announced that VS-5584 has received orphan drug designation from the U.S. Food and Drug Administration for use in the treatment of mesothelioma.
Sign-up for Verastem Receives Orphan Drug Designation from FDA for VS-5584 in Mesothelioma investment picks
2015/2/12
Radian Group Inc. (NYSE: RDN) today reported net income for the quarter ended December 31, 2014, of $428.3 million, or $1.78 per diluted share.
Sign-up for Radian Reports Fourth Quarter and Full Year 2014 Financial Results investment picks
2015/2/12
Incyte Corporation (Nasdaq: INCY) today reported 2014 fourth-quarter and year-end financial results, including revenue from Jakafi ® (ruxolitinib). The Company provided 2015 financial guidance while outlining its progress in recruiting multiple pivotal and proof-of-concept trials, including those investigating its portfolio of JAK inhibitors in a variety of cancer types, its IDO1 inhibitor in combination with other immuno-oncology agents and a series of studies investigating several other innovative targeted therapies in mono- and combination-therapy settings.
Sign-up for Incyte Reports 2014 Fourth-Quarter and Year-End Financial Results; Provides 2015 Financial Guidance; Updates Shareholders on Key Clinical Programs investment picks
2015/2/12
NEWARK, N.Y., Feb.
Sign-up for Ultralife Corporation Reports Fourth Quarter Results investment picks
2015/2/12
Rentech Nitrogen Partners, L.P. (NYSE: RNF) announced today that its Board of Directors has declared a cash distribution of $0.30 per common unit for the fourth quarter of 2014, payable on February 27, 2015 to holders of record as of February 23, 2015.
Sign-up for Rentech Nitrogen Partners, L.P. Announces Fourth Quarter 2014 Distribution investment picks
2015/2/12
Navigant (NYSE: NCI) today announced financial results for the fourth quarter and full year ended December 31, 2014.
Sign-up for Navigant Reports Fourth Quarter and Full Year 2014 Financial Results investment picks
Start Premium Trial Register For Free

P F Fund Financial Data (13,000+ funds)
P F Stock Financial Data (7,000+ stocks)
P F Stock and Fund Screeners (basic)
P F Investing Articles and Market Commentary
P F Articles Archive (>30 days)
P F Discuss (dozens of stock, fund, bond, and general bulletin boards)
P F Portfolio Manager (basic)
P F Morningstar Investment Classroom
P F Access Your Portfolio Anytime, Anywhere via Your Mobile Device
P   Morningstar Fund Analyst Reports (full research on 1,700 funds, ETFs, and CEFs)
P   Morningstar Stock Analyst Reports (full research on more than 1,100 stocks)
P   Portfolio Manager (advanced with 10 X-Ray analyses, including recommendations)
P   Portfolio Monitor (monthly and on-demand personalized portfolio statements)
P   Morningstar Proprietary Stock Information (stock star ratings, buy/sell prices, economic moat ratings, and more)
P   Morningstar 5-Star Stock and Fund Favorites & Red Flags eNewsletters
P   Premium Stock and Fund Screeners (advanced with nearly infinite ways to find the best securities for you)
P   Discounts on Morningstar newsletters, books, seminars, and more

Sign-up to Morningstar


Basic Access

Articles and Videos
Morningstar video reports, articles, data, and tools. Dig into our lineup of e-newsletters and investing classroom courses outlining sensible strategies for maximizing your investments.
Morningstar Discuss
Follow the buzz on individual stocks or fund families. Plus, read the latest posts from Morningstar members and analysts.
Portfolio Manager
Track your investments and watch lists with our Portfolio Manager. Customize your view with our comprehensive stock, fund, and ETF data.

Access these features and more when you sign up for Free Membership.
Join Morningstar today. It's Free.

Unlimited Access

Analyst Research
Gather in-depth, actionable insight on over 3,700 stock and mutual funds covered by Morningstar analysts. View our mutual fund Analyst Reports favored by professionals, savvy experienced investors, and new investors researching options for retirement savings, college plans, or other investment needs.
Portfolio X-Ray®
Ensure your portfolio is positioned exactly how you want with Morningstar's X-Ray Interpreter and Stock Intersection tools. A Barron's "Best of the Web" award winner for five years running, X-Ray Interpreter goes under the hood of your portfolio to provide a useful allocation, sector, and geographic analysis. And you can discover how much of a stock you really own, individually and through mutual funds, with Stock Intersection.
Investment Picks
Find new 5-star stocks (greatly undervalued companies) to consider daily. Our 5-star stock rating is a proven winner, consistently beating benchmarks like the S&P 500. Plus, browse our Fund Analyst Picks and Stewardship Grades to find shareholder-friendly mutual funds that are poised for outperformance.
Portfolio Monitor
Get a clear view of your investments with personalized reports about your portfolio. Receive monthly statements and generate reports on-demand to help you stay on track to meet your investment goals.

Access these features and more when you sign up for Premium Membership.
Start your free 14-day trial today online
Your subscription may be tax deductible. Please contact your tax advisor.

Articles From: Coca-Cola Enterprises, Inc. Reports Fourth-Quarter and Full-Year 2014 Results to Navigant Reports Fourth Quarter and Full Year 2014 Financial Results
Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol |  Title Star Rating |  Category |  Total Assets |  Top Holdings |  Top Sectors |  Symbol |  Name Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol / Ticker |  Title Star Rating |  Category |  Total Assets |  Symbol / Ticker |  Name Title |  Date |  Author |  Collection |  Popularity |  Interest Title |  Date |  Company |  Symbol |  Interest |  Popularity Title |  Date |  Company |  Symbol |  Interest |  Popularity Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Popularity |  Our Choices |  Most Recent